Published 2 days ago • loading... • Updated 1 day ago

Innovent's Dual-Action Obesity Drug Takes On Semaglutide: Phase 3 Trial Reveals 73% Liver Fat Reduction

On May 15, 2025, Innovent Biologics announced the first participant was dosed in GLORY-3, a Phase 3 trial in China comparing mazdutide and semaglutide for adults with overweight or obesity and MAFLD.
This trial follows a Phase 2 study showing mazdutide, a dual GCG/GLP-1 receptor agonist, reduced liver fat by 73.3% in 24 weeks and body weight by 18.6% over 48 weeks in Chinese adults with obesity, supporting its further evaluation.
Mazdutide offers comprehensive metabolic benefits beyond GLP-1 receptor agonists by enhancing lipolysis and fatty acid oxidation, targeting overweight or obese patients with MAFLD, a leading chronic liver disease linked to obesity affecting 81.8% of obese individuals in China.
The GLORY-3 study plans to enroll about 470 participants with BMI ≥27 kg/m2, using liver fat content measured by MRI-PDFF and body weight change at week 48 as primary endpoints, aiming to address the rising obesity and MAFLD burden in China.
Innovent’s continued advancement of mazdutide, with two NDAs under review and several Phase 3 trials underway, underscores the pressing need for effective and safe treatments for obesity and MAFLD, offering the potential to enhance overall well-being and clinical results for patients in China.

Insights by Ground AI

Does this summary seem wrong?

37 Articles

All

Left

Center

Right

Montana Standard

+35 Reposted by 35 other sources

Center

Second Head-to-head Phase 3 Study of Mazdutide versus Semaglutide Completes First Participant Dosing in Adults in China with Overweight or Obesity Accompanied Fatty Liver Disease (GLORY-3)

SAN FRANCISCO and SUZHOU, China, May 15, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncologic, autoimmune, cardiovascular and metabolic, ophthalmologic and other major…

2 days ago

Read Full Article